BRIM
全福生物科技股份有限公司
BRIM is a Taiwan TWSE-listed biotechnology company; its most advanced asset is BRM411 (Phase 2 recruiting, Glaucoma), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| BRM411 | — | Phase 2 recruiting | Glaucoma | Taiwan | 2026-08-25 | Company disclosure |
| BRM421 | — | Phase 2 recruiting | Dry eye disease | Taiwan | 2026-08-25 | Company disclosure |
| BRM424 | — | Phase 2 topline results reported | Neurotrophic keratitis | United States, Brazil | 2026-09-21 | Company disclosure |
Key events
- BRM424 Phase 2 topline results reported in neurotrophic keratitis (company disclosure)
- BRM424 Phase 2 dosing completion announced (company disclosure)